By Professor Jerry Richard Greenfield

Journal articles

de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes, Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597

O'Donnell JEM; Hastings LA; Briody JN; Chan CL; Colombo C; Douglas TA; Freedman SD; Gonska T; Greenfield JR; Leung DH; Lim AYL; Moran A; Prentice BJ; Putman MS; Trotter M; Tullis E; Westall GP; Verge CF; Wainwright CE; Ooi CY; Engelhardt JF; Katz T; King S; Lewindon PJ; Matson AG; McDonald CM; Moheet A; Narkewicz MR; Oliver M; Ramm GA; Sellers ZM; Wilschanski M, 2024, 'SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium', Pediatric Pulmonology, 59, pp. 1661 - 1676, http://dx.doi.org/10.1002/ppul.26970

Forner P; Snaith J; Greenfield JR, 2024, 'Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists', Internal Medicine Journal, 54, pp. 779 - 785, http://dx.doi.org/10.1111/imj.16312

Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2024, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, 54, pp. 559 - 567, http://dx.doi.org/10.1111/imj.16203

Lasschuit JWJ; Center JR; Greenfield JR; Tonks KTT, 2024, 'Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial', Journal of Diabetes and its Complications, 38, http://dx.doi.org/10.1016/j.jdiacomp.2024.108718

Patel SK; Fourlanos S; Greenfield JR, 2024, 'Classification of type 1 diabetes: A pathogenic and treatment-based classification', Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 18, http://dx.doi.org/10.1016/j.dsx.2024.102986

Raven LM; Brown C; Greenfield JR, 2024, 'Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists', Medical Journal of Australia, 220, pp. 14 - 16, http://dx.doi.org/10.5694/mja2.52170

Shen I; Stojanova J; Yeo M; Olsen N; Lockart I; Wang M; Roggeveld J; Heerspink HJL; Greenfield JR; Day R; Danta M, 2024, 'A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.16139

Lamaro BD; Greenfield JR; Snaith JR, 2024, 'Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes', Journal of Patient Experience, 11, http://dx.doi.org/10.1177/23743735241257811

Frampton R; Snaith JR; Hocking S; Holmes-Walker J; Olsen N; Greenfield JR, 2024, 'Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial', Diabetic Medicine, http://dx.doi.org/10.1111/dme.15377

Hayes AG; Penny MJ; Aivazian K; Greenfield JR, 2024, 'Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly.', JCEM Case Rep, 2, pp. luae071, http://dx.doi.org/10.1210/jcemcr/luae071

Raven LM; Muir CA; Deveza RC; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Hayward CS; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation', JHLT Open, pp. 100088 - 100088, http://dx.doi.org/10.1016/j.jhlto.2024.100088

Raven LM; Cao JY; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Fournier’s gangrene in recent transplant recipient on empagliflozin', JHLT Open, 4, pp. 100060 - 100060, http://dx.doi.org/10.1016/j.jhlto.2024.100060

Jeyakumar S; Jeyakumar R; Robson D; Honeysett L; Raven L; Campos Deveza e Silva R; Jabbour A; Kotlyar E; Keogh A; Greenfield J; MacDonald P; Hayward C; Muthiah K, 2024, 'Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in End-Stage Heart Failure Patients Considered for Heart Transplantation', The Journal of Heart and Lung Transplantation, 43, pp. S106 - S106, http://dx.doi.org/10.1016/j.healun.2024.02.213

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Hayward CS; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Safety of Sodium Glucose Co-Transporter 2 Inhibitor Exposure Prior to Heart Transplantation', The Journal of Heart and Lung Transplantation, 43, pp. S148 - S149, http://dx.doi.org/10.1016/j.healun.2024.02.302

Raven LM; Stoita A; Feller RB; Brown C; Greenfield JR, 2023, 'Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists', American Journal of Medicine, 136, pp. e233 - e234, http://dx.doi.org/10.1016/j.amjmed.2023.07.016

Brzozowska MM; Isaacs M; Bliuc D; Baldock PA; Eisman JA; White CP; Greenfield JR; Center JR, 2023, 'Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-33317-6

Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5

Chavali S; Barua S; Adji A; Robson D; Raven LM; Greenfield JR; Eckford H; Macdonald PS; Hayward CS; Muthiah K, 2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, 391, http://dx.doi.org/10.1016/j.ijcard.2023.131259

Hayes AG; Raven LM; Viardot A; Kotlyar E; Greenfield JR, 2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903

Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068

Snaith JR; Olsen N; Kowalski G; Bruce C; Holmes-Walker J; Greenfield JR, 2023, 'OR18-03 Peripheral But Not Hepatic Insulin Resistance Associates With Adverse Vascular And Metabolic Health In Type 1 Diabetes: A Possible Target For Adjunctive Therapy', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.895

Raven LM; Muir CA; Kessler Iglesias C; Kotlyar E; Muthiah K; Bart NK; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.733

Raven LM; Muir CA; Greenfield JR, 2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia, 219, pp. 293 - 294, http://dx.doi.org/10.5694/mja2.52067

Sheu A; Blank RD; Tran T; Bliuc D; Greenfield JR; White CP; Center JR, 2023, 'Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study', JBMR Plus, 7, http://dx.doi.org/10.1002/jbm4.10780

Raven LM; Muir CA; Pouliopoulos J; Hayward CS; Macdonald PS; Greenfield JR; Jabbour A, 2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation, 32, pp. 1076 - 1079, http://dx.doi.org/10.1016/j.hlc.2023.05.014

Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)', European Journal of Clinical Pharmacology, 79, pp. 1239 - 1248, http://dx.doi.org/10.1007/s00228-023-03539-8

Chowdhury G; Carland JE; Kumar S; Olsen N; Graham G; Kumarasinghe G; Hayward CS; Greenfield JR; Macdonald P; Day RO; Stocker SL, 2023, 'The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study', British Journal of Clinical Pharmacology, 89, pp. 2603 - 2613, http://dx.doi.org/10.1111/bcp.15737

RAVEN LM; MUIR CA; POULIOPOULOS JIM; MACDONALD PS; JABBOUR A; GREENFIELD J, 2023, '1438-P: Diabetes after Cardiac Transplant with Low-Dose Everolimus and Tacrolimus', Diabetes, 72, http://dx.doi.org/10.2337/db23-1438-p

Lasschuit JWJ; Greenfield JR; Tonks KTT, 2023, 'Response to the Letter to the Editor regarding “Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus”', Acta Diabetologica, 60, pp. 713 - 714, http://dx.doi.org/10.1007/s00592-023-02052-9

Raven LM; Muir CA; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists', Acta Diabetologica, 60, pp. 471 - 480, http://dx.doi.org/10.1007/s00592-022-02018-3

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-069641

Cooper B; Blaker K; Greenfield JR, 2023, 'Olanzapine-induced multifactorial chylomicronaemia syndrome: a rare but important complication', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2023, http://dx.doi.org/10.1530/EDM-22-0225

Sheu A; Greenfield JR; White CP; Center JR, 2023, 'Contributors to impaired bone health in type 2 diabetes', Trends in Endocrinology and Metabolism, 34, pp. 34 - 48, http://dx.doi.org/10.1016/j.tem.2022.11.003

Snaith JR; Greenfield JR; Malozowski S; Weghuber D; Kelly AS; Arslanian S, 2023, 'Once-Weekly Semaglutide in Adolescents with Obesity', New England Journal of Medicine, 388, pp. 1145, http://dx.doi.org/10.1056/NEJMc2300510

Raven LM; Greenfield JR; Muir CA, 2023, 'Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.', JCEM Case Rep, 1, pp. luac017, http://dx.doi.org/10.1210/jcemcr/luac017

Koay YC; Coster ACF; Chen DL; Milner B; Batarseh A; O’Sullivan JF; Greenfield JR; Samocha-Bonet D, 2022, 'Metabolomics and Lipidomics Signatures of Insulin Resistance and Abdominal Fat Depots in People Living with Obesity', Metabolites, 12, pp. 1272, http://dx.doi.org/10.3390/metabo12121272

Moxham R; Greenfield JR; Viardot A; Wu KHC, 2022, 'Tip of the iceberg: are we missing undiagnosed patients with maturity onset diabetes of the young?', Internal Medicine Journal, 52, pp. 2011 - 2012, http://dx.doi.org/10.1111/imj.15948

Patel SK; Ma CS; Bell KJ; Oram R; Hagopian WA; Fourlanos S; Greenfield JR, 2022, 'Immunophenotype and genetic risk scores to improve autoantibody negative type 1 diabetes classification: study protocol', International Journal of Clinical Trials, 9, pp. 293 - 293, http://dx.doi.org/10.18203/2349-3259.ijct20222690

Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727

Raven LM; Morris P; Greenfield JR, 2022, 'Hyperglycaemia induced by gamma-butyrolactone', Diabetic Medicine, 39, http://dx.doi.org/10.1111/dme.14850

Snaith JR; Greenfield JR, 2022, 'Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?', Medical Journal of Australia, 217, pp. 126 - 128, http://dx.doi.org/10.5694/mja2.51637

Brzozowska M; Isaacs M; Bliuc D; Baldock P; Eisman J; White C; Greenfield J; Center J, 2022, 'Effects of bariatric surgery and dietary intervention on changes in insulin resistance and appetite hormones over the period of 3 years', Endocrine Abstracts, http://dx.doi.org/10.1530/endoabs.81.rc5.6

Sheu A; Greenfield JR; White CP; Center JR, 2022, 'Assessment and treatment of osteoporosis and fractures in type 2 diabetes', Trends in Endocrinology and Metabolism, 33, pp. 333 - 344, http://dx.doi.org/10.1016/j.tem.2022.02.006

Raven LM; Mccormack AI; Greenfield JR, 2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768, http://dx.doi.org/10.1210/clinem/dgab822

Lasschuit JWJ; Greenfield JR; Tonks KTT, 2022, 'Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus', Acta Diabetologica, 59, pp. 217 - 224, http://dx.doi.org/10.1007/s00592-021-01803-w

Bennett MJ; Balcerek MI; Lewis EAD; Zhang RLL; Bachmeier C; Tey S; Faux S; Girgis L; Greenfield JR; Lazarus S; Bennett M, 2022, 'Voriconazole-Associated Periostitis: New Insights into Pathophysiology and Management', JBMR Plus, 6, pp. e10557, http://dx.doi.org/10.1002/jbm4.10557

Dahiya S; Tisch S; Greenfield J, 2022, 'The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis', Clinical Parkinsonism and Related Disorders, 6, http://dx.doi.org/10.1016/j.prdoa.2022.100133

Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117

Chavali S; Muthiah K; Hayward C; Macdonald P; Robson D; Greenfield J; Raven L, 2022, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported With Left Ventricular Assist Devices', Heart, Lung and Circulation, 31, pp. S100 - S100, http://dx.doi.org/10.1016/j.hlc.2022.06.124

Back to profile page